1. Home
  2. LBRT vs ERAS Comparison

LBRT vs ERAS Comparison

Compare LBRT & ERAS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Liberty Energy Inc.

LBRT

Liberty Energy Inc.

HOLD

Current Price

$31.82

Market Cap

5.4B

Sector

Energy

ML Signal

HOLD

Logo Erasca Inc.

ERAS

Erasca Inc.

HOLD

Current Price

$11.27

Market Cap

5.5B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
LBRT
ERAS
Founded
2011
2018
Country
United States
United States
Employees
N/A
N/A
Industry
Oilfield Services/Equipment
Biotechnology: Pharmaceutical Preparations
Sector
Energy
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
5.4B
5.5B
IPO Year
2017
2021

Fundamental Metrics

Financial Performance
Metric
LBRT
ERAS
Price
$31.82
$11.27
Analyst Decision
Buy
Strong Buy
Analyst Count
12
12
Target Price
$27.50
$14.25
AVG Volume (30 Days)
3.5M
7.8M
Earning Date
04-22-2026
05-08-2026
Dividend Yield
1.06%
N/A
EPS Growth
N/A
36.23
EPS
0.14
N/A
Revenue
$4,006,116,000.00
N/A
Revenue This Year
$0.27
N/A
Revenue Next Year
$7.44
N/A
P/E Ratio
$234.57
N/A
Revenue Growth
N/A
N/A
52 Week Low
$9.90
$1.06
52 Week High
$34.48
$24.28

Technical Indicators

Market Signals
Indicator
LBRT
ERAS
Relative Strength Index (RSI) 48.81 43.42
Support Level $30.75 $9.80
Resistance Level $32.40 $16.14
Average True Range (ATR) 1.36 0.69
MACD -0.27 0.23
Stochastic Oscillator 28.43 75.51

Price Performance

Historical Comparison
LBRT
ERAS

About LBRT Liberty Energy Inc.

Liberty Energy Inc is a integrated energy services and technology company focused on providing hydraulic fracturing services and related technologies to onshore oil and natural gas exploration and production (E&P) companies. The Company offers customers with hydraulic fracturing services, together with complementary services including wireline services, proppant delivery solutions, field gas processing and treating, compressed natural gas (CNG) delivery, data analytics, related goods (including sand mine operations), and technologies to facilitate lower emission completions, thereby helping customers reduce emissions profile. The company provides services across USA and Canada.

About ERAS Erasca Inc.

Erasca Inc is a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. Its focused RAS/MAPK pathway pipeline comprises modality-agnostic programs aligned with three therapeutic strategies of: targeting key upstream and downstream signaling nodes in the RAS/MAPK pathway; targeting RAS directly; and targeting escape routes that emerge in response to treatment. Its pipeline includes two clinical-stage programs (ERAS-0015, a pan-RAS molecular glue; and ERAS-4001, a pan-KRAS inhibitor), and ERAS-12, a discovery-stage program.

Share on Social Networks: